'India continued with Covishield even after adverse reports': AAP's Saurabh Bharadwaj targets Centre as AstraZeneca admits side effect
The AAP leader's remarks came a day after British pharma giant AstraZeneca admitted in a UK court that its anti-COVID vaccine sold globally as Covishield and Vaxzevria may cause Thrombocytopenia Syndrome (TTS) in "very rare cases."